早期与延迟的贝利穆马布治疗系统性红斑狼的成本效益
Sabrina Hundal1,2, Julian Cappelli3, Christopher Sjöwall4
1Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
JAMA network open
|February 19, 2026
概括
早期启动贝利马布 (系统性红斑狼 (SLE) 的生物疗法) 改善了健康结果,并降低了活跃SLE患者的成本. 这些发现支持较早的临床使用和长期价值的补偿考虑.
科学领域:
- 类风湿病学 类风湿病学
- 卫生经济学 卫生经济学
- 药物经济学 药物经济学
背景情况:
- 贝利马布是一种生物治疗活性,自身抗体阳性系统性红斑狼 (SLE) 的疗法.
- 新出现的证据表明,早些时候启动贝利穆马布可能会改善反应率,实现缓解或降低疾病活性.
- 目前的指导方针往往保留贝利马布用于耐火性疾病.
研究的目的:
- 评估早期和延迟开启贝利马布的经济和健康相关结果,对具有活跃SLE的生物无知患者进行评估.
- 为了比较belimumab早期和延迟启动之间的医疗费用和质量调整寿命年 (QALYs).
- 从美国付款人的角度评估早期开启贝利穆马布的成本效益.
主要方法:
- 使用马尔科夫模型进行的成本效益分析,每月周期在15年的时间范围内.
- 通过对2013年至2025年发表的研究进行有针对性的文献综述,提供了信息.
- 包括具有活跃疾病 (SLE疾病活动指数2000分数>0) 的生物素朴的成人SLE患者.
主要成果:
- 早期开启贝利马布的治疗,额外增加了0.30个QALY,每名患者的增量成本较低,为-126,337.12美元.
- 增量成本效益比率 (ICER) 为每QALY-421,123.73美元,表明成本效益.
- 在81.3%的模拟中,在每QALY值为5万美元的早期启动是首选.
结论:
- 在活跃SLE的生物无知患者中,早期启动贝利马布与改善健康结果和降低整体成本有关.
- 这些发现支持早些时候采用belimumab的临床实验.
- 建议重新考虑报销标准,以反映早期开启贝利穆马布的长期价值.
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...